Antibody Therapeutics XChange Europe

November 22, 2022
Zurich, CH

Join Thomas Schirrmann, André Frenzel and executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics. Learn how YUMAB’s fully human antibody platform creates value in any drug discovery and development program.

Arrange a meeting

People attending from YUMAB:


Thomas Schirrmann, PhD
Founder & CEO


André Frenzel, PhD
Founder & CSO